Contribute Try STAT+ Today

Hello, everyone, and welcome to another working week. We hope the weekend respite was sufficiently distracting, if not restful, given that what now constitutes the usual routine has returned. By this we mean Zoom calls and more Zoom calls, and deadlines and those sorts of things. To cope, yes, we are firing up the coffee kettle and reaching for a cup of stimulation. Our choice today is old-fashioned hazelnut. Feel free to join us. Meanwhile, here are a few tidbits to get you going. Hope your day goes well, and stay safe. …

Hackers linked to Iran have targeted staff at Gilead Sciences (GILD) in recent weeks, according to publicly available web archives reviewed by Reuters and three cybersecurity researchers, as the company races to deploy an experimental treatment for the Covid-19 virus. In one case, a fake email login page designed to steal passwords was sent in April to a top Gilead executive involved in legal and corporate affairs, according to an archived version on a website used to scan for malicious web addresses. Reuters was not able to determine whether the attack was successful.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • May one observe that it seems “all roads lead” to Catalent? After J&J announcing last week that they would be using Catalent as a partner to produce their vaccine candidate, we now have this – Pfizer is freeing up capability to make THEIR experimental vaccine candidate and therefore “is tapping its network of around 200 outside contractors, which includes Catalent … to play a bigger role in producing some of its existing medicines.”

Comments are closed.